Form 8-K · Current Report · Filed 2025-12-15
Cencora Announces Acquisition of OneOncology for $5B
On December 12, 2025, Cencora, Inc. announced its agreement to acquire the majority of the outstanding equity interests of OneOncology from TPG and other shareholders for approximately $3.6 billion and retire its existing corporate debt of $1.3 billion, for a total cash consideration of approximately $5.0 billion. The transaction is expected to close by the end of Cencora's fiscal 2026 second quarter, subject to regulatory approvals. Cencora plans to fund the transaction through new debt financing and expects the acquisition to be approximately neutral to its adjusted diluted EPS in the first twelve months following close. Cencora has also raised its long-term guidance expectations to reflect the expected contribution from OneOncology.
- Filer
- Cencora Inc. COR · NYSE
- Filed
- Accession
- 0001104659-25-120852
- CIK
- 0001140859
- Signal
- High impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Regulation FD Disclosure
Other Events
Financial Statements and Exhibits
Market reaction
Close before filing
$346.00
Next session
-1.2%
Since filing
-10.0%
Latest close
$311.34
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from COR reporting the same item, with the next session's move:
About Cencora Inc.
Cencora Inc., formerly known as AmerisourceBergen Corporation, represents a pivotal entity in the global healthcare distribution and services sector. As a leading pharmaceutical sourcing and distribution services company, Cencora Inc. plays a critical role in ensuring the efficient supply of pharmaceutical products to a range of healthcare providers, including hospitals, pharmacies, and clinics. Its business model is centered on the seamless integration of logistics, consulting services, and the provision of innovative solutions aimed at improving pharmaceutical supply chain operations. Cencora Inc. impacts various segments of the healthcare industry by enhancing the availability and accessibility of healthcare products. Known for its global reach and extensive network of distribution centers, the company supports the delivery of critical medications and healthcare products across numerous geographies. Cencora Inc.'s significance in the market is underscored by its ability to partner with pharmaceutical manufacturers and healthcare providers to streamline processes, reduce costs, and improve patient outcomes. Headquartered in Conshohocken, Pennsylvania, Cencora Inc. remains a cornerstone of the healthcare distribution market, focusing on sustainability, innovation, and strategic collaborations.
Never miss another COR filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.